Editorial: H-RAS controls phenotypic profiles of vascular smooth muscle cells and the pathogenesis of vascular proliferative disorders

Circulation Research

Volumn 104, Issue 10, 2009, Pages 1139-1141

  Ramos, Kenneth S ^a,b  

^a University of Louisville School of Medicine   (United States)

^b Delia Baxter Research Building ^*  (United States)

Author keywords

H RAS; Vascular proliferative disorders; Vascular smooth muscle cell differentiation; Vascular smooth muscle cell phenotypes; Vascular smooth muscle cell proliferation

Indexed keywords

3 DEAZAADENOSINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P21;

CELL CYCLE PROGRESSION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; DRUG MECHANISM; EDITORIAL; HUMAN; INTIMA; ONCOGENE H RAS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; ANIMAL; C57BL MOUSE; CELL MOTION; MALE; METABOLISM; MOUSE; NOTE; PATHOLOGY;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SMOOTH, VASCULAR; PHENOTYPE; PROTO-ONCOGENE PROTEINS P21(RAS); VASCULAR DISEASES;

EID: 66949126130     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.199554     Document Type: Editorial

References (22)

1. Schwartz SM, Gajdusek CM. Growth factors and the vessel wall. Prog Hemost Thromb. 1982;6:85-112.
2. Williams LT, Tremble P, Antoniades HN. Platelet-derived growth factor binds specifically to receptors on vascular smooth muscle cells and the binding becomes nondissociable. Proc Natl Acad Sci U S A. 1982;79: 5867-5870.
3. Brown KE, Kindy MS, Sonenshein GE. Expression of the c-myb proto-oncogene in bovine vascular smooth muscle cells. J Biol Chem. 1992; 267:4625-4630.
4. Simons M, Rosenberg RD. Antisense nonmuscle myosin heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ Res. 1992;70:835-843.
5. Parks JL, Cardell RR, Hubbard FC Jr, Hubbard D, Meltzer A, Penn A. Cultured human atherosclerotic plaque smooth muscle cells retain transforming potential and display enhanced expression of the myc protoon-cogene. Am J Pathol. 1991;138:765-775.
6. Edelman ER, Simons M, Sirois MG, Rosenberg RD. c-myc in vasculo-proliferative disease. Circ Res. 1995;76:176-182.
7. Sadhu DN, Ramos KS. Cyclic AMP inhibits c-Ha-ras protooncogene expression and DNA synthesis in rat aortic smooth muscle cells. Experientia. 1993;49:567-570.
8. Sadhu DN, Merchant M, Safe SH, Ramos KS. Modulation of protoon-cogene expression in rat aortic smooth muscle cells by benzo(a)pyrene. Arch Biochem Biophy. 1993;300:263-268.
9. Indolfi C, Avvedimento EV, Rapacciuolo A, Di Lorenzo E, Esposito G, Stabile E, Feliciello A, Mele E, Giuliano P, Condorelli G, Chiariello M. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med. 1995;1:541-545.
10. Ellis RW, DeFeo D, Shih TY, Gonda MA, Young HA, Tsuchida N, Lowy DR, Scolnick EM. The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature. 1981;292:506-511.
11. Davis M, Malcolm S, Hall A, Marshall CJ. Localisation of the human N-ras oncogene to chromosome 1cen-p21 by in situ hybridization. EMBO J. 1983;2:2282-2283.
12. Ramos KS. Redox regulation of c-Ha-ras and osteopontin signaling in vascular smooth muscle cells: implications in chemical atherogenesis. Annu Rev Pharmacol Toxicol. 1999;39:243-265.
13. Marshall MS. Ras target proteins in eukaryotic cells. FASEB J. 1995;9: 1311-1318.
14. Reddy EP, Reynolds RK, Santos E, Barbacid M. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature. 1982;300:149-152.
15. Marx J. Forging a path to the nucleus. Science. 1993;260:1588-1590.
16. Derijard B, Hibi M, Wu I-H, Barrett T, Su B, Deng T, Karin M, Davis RJ. JNK1: a protein kinase stimulated by UV light and Ha-ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994;71:1081-1091.
17. Ramos KS, Zhang Y, Sadhu DN, Chapkin RC. The induction of prolif-erative phenotypes in vascular smooth muscle cells by benzo(a) pyrene is characterized by upregulation of phosphatidylinositol metabolism and c-Ha-ras gene expression. Arch Biochem Biophys. 1996;332:213-222.
18. Sadhu DN, Lundberg MS, Burghardt RB, Ramos KS. C-Ha-rasEJ trans-fection of rat aortic smooth muscle cells induces epidermal growth factor responsiveness and characteristics and a malignant phenotype. J Cell Physiol. 1994;161:490-500.
19. Weber TJ, Ramos KS. c-Ha-rasEJ transfection in vascular smooth muscle cells circumvents PKC requirement during mitogenic signaling. Am J Physiol. 1997;273:H1920-H1926.
20. Ueno H, Yamamoto H, Ito S, Li JJ, Takeshita A. Adenovirus-mediated transfer of a dominant-negative H-ras suppresses neointimal formation in balloon-injured arteries in vivo. Arterioscler Thromb Vasc Biol. 1997;17: 898-904. (Pubitemid 27209267)
21. Work LM, McPhaden AR, Pyne NJ, Pyne S, Wadsworth RM, Wainwright CL. Short-term local delivery of an inhibitor of Ras farnesyltransferase prevents neointima formation in vivo after porcine coronary balloon angioplasty. Circulation. 2001;104:1538-1543.
22. Sedding DG, Tröbs M, Reich F, Walker G, Fink L, Haberbosch W, Rau W, Tillmanns H, Preissner KT, Bohle RM, Langheinrich AC. 3-Deazaadenosine prevents smooth muscle cell proliferation and neointima formation by interfering with Ras signaling. Circ Res. 2009;104:1192-1200.